| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Parita Shah, Eric Plitman, Yusuke Iwata, Julia Kim, Shinichiro Nakajima, Nathan Chan, Eric E Brown, Fernando Caravaggio, Edgardo Torres, Margaret Hahn, M Mallar Chakravarty, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrer. Glutamatergic neurometabolites and cortical thickness in treatment-resistant schizophrenia: Implications for glutamate-mediated excitotoxicity. Journal of psychiatric research. vol 124. 2021-05-14. PMID:32169688. |
the present study had two main aims: (1) to explore differences in cortical thickness between patients with treatment-resistant schizophrenia non-responsive to clozapine (ultra-treatment-resistant schizophrenia, utrs), patients with treatment-resistant schizophrenia responsive to clozapine (cloz-resp), patients responsive to first-line non-clozapine antipsychotics (fl-resp), and healthy controls (hcs); and (2) to test our hypothesis of structural compromise as a manifestation of neurotoxic effects from elevated glutamate (glu) (i.e. |
2021-05-14 |
2023-08-13 |
Not clear |
| Pramod C Nair, Ross A McKinnon, John O Miners, Tarun Bastiampilla. Binding of clozapine to the GABA Molecular psychiatry. vol 25. issue 9. 2021-05-14. PMID:32203158. |
binding of clozapine to the gaba clozapine is the gold-standard agent for treatment resistant schizophrenia but its mechanism of action remains unclear. |
2021-05-14 |
2023-08-13 |
Not clear |
| Takeo Hata, Tetsufumi Kanazawa, Takeshi Hamada, Masami Nishihara, Hiroshi Yoneda, Miki Nakajima, Takahiro Katsumat. The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan. Journal of psychiatric research. vol 127. 2021-05-14. PMID:32450360. |
although the use of antipsychotics for schizophrenia in japan mostly corresponds to various clinical guidelines, limited use of clozapine and lais was identified. |
2021-05-14 |
2023-08-13 |
Not clear |
| Seyed Alireza Hosseini, Brianna Skrzypcak, Rama Yasaei, Sara Abdijadid, Fowrooz Joolhar, Theingi Tiffany Win, Leila Moosav. Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis. The American journal of case reports. vol 21. 2021-05-14. PMID:33137026. |
background clozapine plays a unique role in the management of treatment-resistant schizophrenia (trs). |
2021-05-14 |
2023-08-13 |
Not clear |
| Seyed Alireza Hosseini, Brianna Skrzypcak, Rama Yasaei, Sara Abdijadid, Fowrooz Joolhar, Theingi Tiffany Win, Leila Moosav. Successful Clozapine Re-Challenge After Suspected Clozapine-Induced Myocarditis. The American journal of case reports. vol 21. 2021-05-14. PMID:33137026. |
case report we present the case of a 22-year-old hispanic man with treatment-resistant schizophrenia and polysubstance use disorder (methamphetamine, cannabis, and alcohol) initiated on aggressive clozapine titration after lack of response to several other therapies. |
2021-05-14 |
2023-08-13 |
Not clear |
| Amjad Daaboul, Daniel Sedding, Sebastian Nuding, Artjom Schot. Successful Treatment of an Acute High-Dose Clozapine Poisoning without Detoxication. The American journal of case reports. vol 22. 2021-05-14. PMID:33591960. |
background clozapine is a well-proven atypical antipsychotic drug used for therapy of treatment-resistant schizophrenia. |
2021-05-14 |
2023-08-13 |
Not clear |
| Amjad Daaboul, Daniel Sedding, Sebastian Nuding, Artjom Schot. Successful Treatment of an Acute High-Dose Clozapine Poisoning without Detoxication. The American journal of case reports. vol 22. 2021-05-14. PMID:33591960. |
case report we report the case of a 28-year-old man with prior diagnosed schizophrenia who presumably ingested 8 g (regular maximum daily dose 900 mg/d) of clozapine with uncertain intent. |
2021-05-14 |
2023-08-13 |
Not clear |
| Yusuke Iwata, Shinichiro Nakajima, Eric Plitman, Peter Truong, Ali Bani-Fatemi, Fernando Caravaggio, Julia Kim, Parita Shah, Wanna Mar, Sofia Chavez, Gary Remington, Philip Gerretsen, Vincenzo De Luca, Napapon Sailasuta, Ariel Graff-Guerrer. Glutathione Levels and Glutathione-Glutamate Correlation in Patients With Treatment-Resistant Schizophrenia. Schizophrenia bulletin open. vol 2. issue 1. 2021-05-13. PMID:33969302. |
patients with schizophrenia were categorized into 3 groups with respect to their antipsychotic response: (1) clozapine (clz) nonresponders, (2) clz responders, and (3) first-line responders (flr). |
2021-05-13 |
2023-08-13 |
Not clear |
| Aleksandar Todorovic, Sweta Lal, Frances Dark, Veronica De Monte, Steve Kisely, Dan Siskin. CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis. Journal of mental health (Abingdon, England). 2021-05-08. PMID:33076721. |
cbtp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis. |
2021-05-08 |
2023-08-13 |
Not clear |
| Aleksandar Todorovic, Sweta Lal, Frances Dark, Veronica De Monte, Steve Kisely, Dan Siskin. CBTp for people with treatment refractory schizophrenia on clozapine: a systematic review and meta-analysis. Journal of mental health (Abingdon, England). 2021-05-08. PMID:33076721. |
cognitive behavioural therapy for psychosis (cbtp), an effective treatment for people with schizophrenia, may have a role in clozapine refractory schizophrenia. |
2021-05-08 |
2023-08-13 |
Not clear |
| Isabella R Willcocks, Sophie E Legge, Mariana Nalmpanti, Lucy Mazzeo, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walters, Antonio F Pardiña. Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia. Frontiers in pharmacology. vol 12. 2021-05-08. PMID:33959025. |
clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. |
2021-05-08 |
2023-08-13 |
Not clear |
| Isabella R Willcocks, Sophie E Legge, Mariana Nalmpanti, Lucy Mazzeo, Adrian King, John Jansen, Marinka Helthuis, Michael J Owen, Michael C O'Donovan, James T R Walters, Antonio F Pardiña. Clozapine Metabolism is Associated With Absolute Neutrophil Count in Individuals With Treatment-Resistant Schizophrenia. Frontiers in pharmacology. vol 12. 2021-05-08. PMID:33959025. |
up to one-third of those with schizophrenia fail to respond to standard antipsychotics and are considered to have treatment-resistant schizophrenia, a condition for which clozapine is the only evidence-based medication. |
2021-05-08 |
2023-08-13 |
Not clear |
| Ebenezer Oloyede, Olubanke Dzahini, Eromona Whiskey, David Taylo. Clozapine and Norclozapine Plasma Levels in Patients Switched Between Different Liquid Formulations. Therapeutic drug monitoring. vol 42. issue 3. 2021-05-05. PMID:31652191. |
clozapine is the drug of choice for treatment-resistant schizophrenia. |
2021-05-05 |
2023-08-13 |
Not clear |
| David Kitchen, Alex Till, Panchu Xavie. Routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia. BJPsych bulletin. 2021-04-29. PMID:33910673. |
routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia. |
2021-04-29 |
2023-08-13 |
Not clear |
| Jurjen J Luykx, Noraly Stam, Antti Tanskanen, Jari Tiihonen, Heidi Taipal. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. The British journal of psychiatry : the journal of mental science. vol 217. issue 3. 2021-04-27. PMID:31910911. |
in the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. |
2021-04-27 |
2023-08-13 |
Not clear |
| J Leijala, O Kampman, J Suvisaari, S Eskeline. Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders. BMC psychiatry. vol 21. issue 1. 2021-04-26. PMID:33441112. |
this study investigated how schizophrenia core symptoms and daily functioning affect treatment adherence and attitudes toward antipsychotic medication and to compare patients using clozapine or other antipsychotics. |
2021-04-26 |
2023-08-13 |
Not clear |
| Naomichi Okamoto, Yuki Konishi, Hirofumi Tesen, Atsuko Ikenouchi, Reiji Yoshimur. A Low Clozapine Dose Improved Refractory Tardive Dystonia without Exacerbating Psychiatric Symptoms: A Case Report. International medical case reports journal. vol 14. 2021-04-24. PMID:33889030. |
clozapine is recommended for patients with schizophrenia and tardive dystonia (td); however, the appropriate dose remains unclear. |
2021-04-24 |
2023-08-13 |
Not clear |
| Naomichi Okamoto, Yuki Konishi, Hirofumi Tesen, Atsuko Ikenouchi, Reiji Yoshimur. A Low Clozapine Dose Improved Refractory Tardive Dystonia without Exacerbating Psychiatric Symptoms: A Case Report. International medical case reports journal. vol 14. 2021-04-24. PMID:33889030. |
herein, we report on a 41-year-old female with schizophrenia and td who was treated with a low clozapine dose. |
2021-04-24 |
2023-08-13 |
Not clear |
| Joomi Lee, Min-Gul Kim, Hyeon-Cheol Jeong, Kwang-Hee Shi. Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia. Translational and clinical pharmacology. vol 29. issue 1. 2021-04-16. PMID:33854999. |
physiologically-based pharmacokinetic model for clozapine in korean patients with schizophrenia. |
2021-04-16 |
2023-08-13 |
Not clear |
| Joomi Lee, Min-Gul Kim, Hyeon-Cheol Jeong, Kwang-Hee Shi. Physiologically-based pharmacokinetic model for clozapine in Korean patients with schizophrenia. Translational and clinical pharmacology. vol 29. issue 1. 2021-04-16. PMID:33854999. |
clozapine has been used as a treatment of schizophrenia. |
2021-04-16 |
2023-08-13 |
Not clear |